Articles

Xhance is the first medication indicated for the treatment of chronic rhinosinusitis without nasal polyps to be approved by the FDA. 

FDA Approves Xhance, Optinose’s Treatment for Adults with Chronic Rhinosinusitis Without Nasal Polyps 

The latest news for pharma industry insiders.

Pharma Pulse 3/18/24: Weight-Loss Drug Through Amazon, Overcoming Gender Inequities in Health Care & more

Michael Christel is Group Managing Editor of Pharmaceutical Commerce, Pharmaceutical Executive, and Applied Clinical Trials. He can be reached at mchristel@mjhlifesciences.com.

Videos

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.

Reading the Tea Leaves on Recent Surge in Pharma Dealmaking

Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.

The Case for Domestic Sourcing to Establish Reliable Pharmaceutical Supply Chains in the United States 

Pharma Pulse 3/15/24: Elranatamab Maintains or Improves Symptoms of Multiple Myeloma Patients,  AI Assistant for Security Products & more

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Getting the Lay of the Land After a Banner Year for Biosimilars

Approval was based on positive data from the Phase III MARCH study across a range of genetic progressive familial intrahepatic cholestasis types. 

FDA Expands Approval of Mirum’s Livmarli for Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

Cancer’s Financial Burden Being Felt Worldwide

Under the group purchasing agreement, the serialization business will be the sole provider of DSCSA services for Premier’s 4,300-plus hospital and health system network. 

News